NEURO-DRAM: a 3D recurrent visual attention model for interpretable
  neuroimaging classification by Wood, David et al.
NEURO-DRAM: a 3D recurrent visual attention
model for interpretable neuroimaging classification
David A. Wood
King’s College London
david.wood@kcl.ac.uk
James H. Cole∗
King’s College London
University College London
james.cole@ucl.ac.uk
Thomas C. Booth ∗
King’s College London
King’s College Hospital
thomas.booth@kcl.ac.uk
For the Alzheimer’s Disease Neuroimaging Initiative
Abstract
Deep learning is attracting significant interest in the neuroimaging community
as a means to diagnose psychiatric and neurological disorders from structural
magnetic resonance images. However, there is a tendency amongst researchers
to adopt architectures optimized for traditional computer vision tasks, rather than
design networks customized for neuroimaging data. We address this by introducing
NEURO-DRAM, a 3D recurrent visual attention model tailored for neuroimaging
classification. The model comprises an agent which, trained by reinforcement
learning, learns to navigate through volumetric images, selectively attending to the
most informative regions for a given task. When applied to Alzheimer’s disease
prediction, NEURO-DRAM achieves state-of-the-art classification accuracy on
an out-of-sample dataset, significantly outperforming a baseline convolutional
neural network. When further applied to the task of predicting which patients
with mild cognitive impairment will be diagnosed with Alzheimer’s disease within
two years, the model achieves state-of-the-art accuracy with no additional training.
Encouragingly, the agent learns, without explicit instruction, a search policy visiting
standardized radiological hallmarks of Alzheimer’s disease, suggesting a route to
automated biomarker discovery for more poorly understood disorders.
1 Introduction
Neuroimaging has long held promise for automating diagnostic and prognostic decisions for psychi-
atric and neurological disorders, based on statistical analysis of brain structure and function. However,
the clinical adoption of automated neuroimaging analysis has been limited to date, in part because
finding subtle and diffuse patterns in high-dimensional brain images that are clinically-meaningful is
challenging, and in part because an intuitive understanding of how automated decisions are reached
has been lacking. In other words, the performance levels and interpretability of neuroimaging analysis
have generally not reached clinically-acceptable thresholds.
In recent years, deep-learning based approaches have attracted substantial interest as a way to improve
model performance and provide new approaches to interpreting modelling decisions. For example, a
number of papers have demonstrated accurate classification of disorders such as Alzheimer’s disease
from structural MRI scans using convolutional neural networks (Spasov et al. (2019), Wegmayr et al.
(2017), Korolev et al. (2017), Cheng et al. (2017), Böhle et al. (2019)). Despite this growing interest,
only modest improvements in model performance have been achieved since the first demonstration
(Vieira et al. (2017)), with limited architectural variety appearing in the literature. We ascribe this to
a trend within the neuroimaging community to adopt those architectures that have proved successful
in computer vision competitions such as the ImageNet Large-Scale Visual Recognition Challenge,
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without considering the peculiarities of neuroimaging data. However, this repurposing of architectures
is potentially problematic for several reasons:
i) The larger number of parameters inherent to 3D networks increases the likelihood of over-fitting to
training data. This is exacerbated by the relative paucity of labelled MRI data, with generalization to
out-of-sample images, such as those taken from different scanners, often quite poor (Wegmayr et al.
(2018), Korolev et al. (2017)).
ii) Standard convolutional architectures cannot flexibly incorporate non-imaging data (Liu, (2019)).
This is particularly problematic for neuroimaging tasks, where clinical and demographic information
constitute useful sources of supplementary information that can help guide a classification decision.
iii) Deep neural networks often face the criticism that they are ‘black-box’, producing highly accurate
but inscrutable predictions (Zeiler and Fergus, (2014), Gilpin et al. (2019)). Although this is not
always an issue in certain accuracy-at-any-cost applications, algorithmic transparency is particularly
critical when employed in clinical settings to engender trust in the diagnostic decision.
iv) GPU memory limitations restrict the possible size of mini-batches used in stochastic gradient-
based optimisers to a small fraction of that possible with 2D images, resulting in high-variance
gradient estimates and unstable learning. This makes networks increasingly sensitive to optimization
hyper-parameters such as the learning rate and its scheduling which, if not set correctly, can result in
the algorithm failing to converge.
In order to overcome these limitations we introduce NEURO-DRAM, a 3D recurrent visual attention
model tailored for neuroimaging classification. NEURO-DRAM comprises an agent which, trained by
reinforcement learning, learns to attend to highly informative volumes within an image, while avoiding
those providing little discriminative value. Because the agent doesn’t process the entire image in a
single step, both the number of trainable parameters and the amount of computation is much lower
than with fully convolutional architectures, leading to faster convergence and better generalization.
Non-imaging information such as clinical and demographic data can also be incorporated by the
model in a natural manner, providing hints on where to look without being directly used for the
final classification decision. Finally, by visualising the agent’s trajectory, the most discriminative
anatomical regions for a given classification task can be obtained, providing a clear insight into
algorithm’s decision.
When applied to the task of Alzheimer’s disease prediction, NEURO-DRAM achieves state-of-
the-art classification accuracy, significantly outperforming a baseline convolutional neural network.
NEURO-DRAM also generalizes to out-of-sample data, exhibiting no performance reduction with
images taken from an external dataset. When further applied to the task of predicting which patients
with mild cognitive impairment will be diagnosed with Alzheimer’s disease within two years, the
agent again achieves state-of-the-art accuracy with no additional training. Encouragingly, the agent
learns, without explicit instruction, a search policy visiting standardized radiological hallmarks of
Alzheimer’s disease, suggesting a route to automated biomarker discovery for more poorly understood
disorders.
2 Previous Work
Several attempts have been made to address the issues outlined in the previous section within the
context of neuroimaging. Spasov et al. (2019) tackled the problem of overfitting by introducing a
parameter-efficient network incorporating separable convolutions and multi-task learning. Large
strides and frequent down-sampling operations were also employed to help reduce the number of
trainable parameters for their network, however this comes at the expense of spatial resolution,
making this approach unsuitable for detecting visually subtle disorders. Data augmentation is another
technique for reducing the extent of overfitting, with several authors applying transformations such
as deformation, rotation, hemisphere flipping, scaling, and cropping to images before training (Böhle
et al. (2019), Esmaeilzadeh et al. (2018), Wegmayr et al. (2018), Basaia et al. (2019)). However,
with registration to a reference template a common preprocessing step, translations and rotations are
not well motivated operations for neuroimaging data. Furthermore, deformations and cropping are
unsuitable for neuroimaging tasks involving patients with severe neuronal atrophy or post-operative
cavities, limiting the applicability of this approach.
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Böhle et al. (2019) addressed the interpretability issue by using layer-wise relevance propagation
(LRP) to help visualise the decision of a convolutional Alzheimer’s disease classifier. Esmaeilzadeh
et al. (2018) took a different approach, performing an occlusion analysis to elucidate their classifier’s
prediction. However, LRP performs a non-unique back-propagation from model parameters to image
voxels (Bach et al. (2015)), while occlusion analysis is confounded by the issues highlighted above
for cropping.
Several attempts have been made to incorporate clinical and demographic information into neu-
roimaging classifiers (Spasov et al. 2019, Esmaeilzadeh et al. 2018), however in these cases this
was achieved by concatenating the information with an image representation learned by a separate
convolutional network. When the non-imaging information is sufficiently informative, this approach
offers the model a ‘shortcut’, whereby it can ignore the imaging information and instead base its
decision solely on the clinical data. Behaviour of this kind is both undesirable, and clearly inflexible
to variable, missing or incomplete clinical information in out-of-sample datasets.
The high computational cost of deep convolutional networks has motivated the introduction of
visual attention mechanisms for computer vision tasks. Mnih et al. (2014) introduced a recurrent
attention model (RAM) which was shown to learn successful policies for cluttered and translated
digit classification tasks, significantly outperforming a baseline convolutional model. Ba et al. (2015)
extended RAM to recognize multiple objects in an image by including a context network to provide
hints about informative regions of the image. This so-called deep recurrent attention model, or
DRAM, outperformed state-of-the-art convolutional networks in a number of transcription tasks,
requiring fewer parameters and less computation.
Our work seeks to address these issues simultaneously, building on the work of Mnih et al. (2014)
and Ba et al. (2015) by tailoring the deep recurrent visual attention model for use with volumetric
images. Like Spasov et al. (2019) we incorporate clinical, demographic, and other non-imaging
data into our classifier, but in a more natural manner that doesn’t allow any shortcut solutions, and
is robust to variable, missing or incomplete information. Finally, we take the view that the most
convincing approach to model explainability is to directly visualise the regions which proved most
informative, rather than attempt to analyse a model’s parameters. As such, we interpret our model’s
trajectory through an image as a natural form of explainability, and suggest a route to automated
biomarker discovery.
3 The 3D recurrent visual attention model
NEURO-DRAM is built around a two-layer recurrent neural network (Fig. 1). At each time step
t the agent receives a small fraction of the entire image, centred around position lt, and uses this
information to decide which location to attend to at the next step t+ 1. After a fixed number of such
steps the agent makes a classification decision, receiving at this point a scalar reward determined by
its classification accuracy. The goal of the agent is to maximize these rewards along its trajectory,
and by doing so it learns to attend to the most informative regions of the image for the task at hand.
Because the model is comprised of several distinct sub-networks, we discuss each of these in turn
below.
Glimpse network
The glimpse network is a non-linear mapping that takes as input a small image volume xt, hereafter a
glimpse, as well as the corresponding location coordinate lt, and outputs a vector gt. The goal of the
glimpse network is to learn a useful representation for gt, summarising what it has seen and where
it has seen it. This is performed in two steps: i) the glimpse xt is processed by a 3D convolutional
neural network, comprising blocks of convolutional layers with batch normalisation and max pooling,
producing a ‘what’ representation gx,t. ii) in parallel, the location coordinate lt is mapped to a
‘where’ vector representation gl,t, by a single-layer fully connected neural network. Following Ba
et al. (2015) and Larochelle & Hinton (2010), gt is produced by element wise multiplication of the
‘what’ and ‘where’ representations:
gt = gx,t  gl,t (1)
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Figure 1: Schematic representation of NEURO-DRAM. At each time step the agent selects a location
to attend to and receives a small ‘glimpse’ centred at this point, outputting a classification decision
after a fixed number of such steps. Trained by reinforcement learning, the agent learns to attend to
informative regions for a given task, avoiding those providing little discriminative value.
Recurrent network
A recurrent neural network is used to build up the agent’s internal representation summarizing
information extracted from past observations. This representation is used by both the location
network, which uses it to determine the next location to attend to lt+1, and by the classification
network which uses it to make a diagnostic decision at the final step. In the present work the recurrent
network consists of two stacked LSTM units (Hochreiter & Schmidhuber, 1997), employed because
of their ability to learn long-range temporal dependencies. The lower LSTM cell takes as input the
glimpse representation gt, producing output r1t which is ultimately used for classification, while the
second cell takes as input r1t , producing r
2
t which is used by the location network (Fig. 1). This
division ensures that the context network cannot directly influence the classification decision, as we
discuss shortly.
Location network
The location network consists of a single-layer fully connected network which maps r2t to a 3D
vector µt in the range [-1,1] which defines the mean of an isotropic 3D normal distribution. lt+1
is then produced by sampling from this parameterized Gaussian, with the variance a fixed hyper-
parameter which controls the exploration/exploitation trade-off ubiquitous in reinforcement learning
(S. Thrun, 1992). This stochasticity in determining the next location helps improve the generalisation
performance of the model, as we describe later.
Non-imaging context network
A context network was first introduced by Ba et al. (2015) to provide the initial state for their recurrent
network. In that work, the context network was a shallow 2D convolutional network, taking as input
a down-sampled (i.e., low resolution) view of the entire image, and was tasked with providing both
the initial glimpse location l0 as well as hints about the locations of potentially informative regions in
the image. Inspired by this we introduce a non-imaging context network consisting of a single-layer
fully connected network which, in the present work, produces the initial recurrent network state r20
from available clinical and demographic information. This contextual information can be used by the
agent to help condition its trajectory, but cannot be used by the classification network to inform the
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final prediction, as we discus below. The input to the non-imaging context network is not limited to
demographic and clinical information, however, and could instead include, for example, radiological
reports, patient clinical history, genetic information and DICOM meta-data.
Classification network
The classification network consists of a single-layer fully connected neural network with a sigmoid
activation function and is used for binary classification, taking as input the final lower LSTM state
vector r1N . As observed by Ba et al. (2015), we found that if the classification network was allowed
to use the representation produced by the context network (in our case clinical and demographic
details), the network could take a shortcut and learn to base its decision entirely on this information.
In order to prevent this undesirable behaviour, the context and classification networks are connected
to different layers of the recurrent network. As such, gradients cannot flow between the classification
and context network, thereby preventing classification optimization on the basis of non-imaging data
from occurring. Instead, the non-imaging information only indirectly influences the classification
decision by directing where the agent moves, and therefore which image volumes it utilises. It is
plausible that this is closer to the manner in which such supplementary information is incorporated
by a clinical radiologist.
Reward
At each time step, in addition to receiving a new glimpse xt the agent receives a scalar reward rt,
and its goal is to maximise the sum of these rewards over the course of its trajectory. In the case
of neuroimaging classification, we set rt equal to 1 for all t if after the final step the classification
(i.e., Alzheimer’s disease versus healthy, brain tumour versus no brain tumour etc.) is correct, and 0
otherwise.
At a high level, NEURO-DRAM can be considered to consist of two collaborative sub-units, one
comprising the context network, glimpse network, and location network, which is tasked with
providing informative visual observations to a second unit, the classification network, which utilizes
these observations to make a diagnostic decision. The model is therefore a visual-based neuroimaging
classifier, with the classification decision based on small but informative MRI volumes, and not
clinical or demographic information.
4 Training
The goal of training is to learn model parameters which maximise the expected reward that the
agent receives by traversing through an image. However, the sampling procedure performed by the
location network introduces discontinuities into the model, precluding the use of standard gradient
backpropagation techniques for parameter optimization. Instead, we employ a hybrid approach,
training the classification network and glimpse networks by standard maximum-likelihood supervised
learning, and the location and context networks by reinforcement learning.
The classification and glimpse network parameters are optimized by minimizing the binary cross
entropy loss between the empirical and predicted label distributions,
−
N∑
i=1
(yi log(pi) + (1− yi) log(1− pi)), (2)
where yi ∈ {0, 1} is the binary label for example i, and pi is the probability, as predicted by the
classifier network, that the i’th example belongs to the positive class. The gradient of this loss can be
back-propagated through these two networks using standard gradient based methods like stochastic
gradient descent, or using more advanced optimization procedures such as ADAM (Kingma et al.
2014) as we do in the experiments below.
Conversely, the parameters θ for the location network and context network are trained by maximising
the expectation of the total reward J , which in turn depends on the classification accuracy,
J(θ) = Eτ∼piθ(τ)
[
T∑
t=1
rt
]
= Eτ∼piθ(τ) [R] , (3)
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with τ denoting the sequence of states and actions during the agent’s trajectory, and piθ(τ) the
policy-dependent distribution over these trajectories. Following Mnih et al. (2014) we employ the
REINFORCE algorithm (Williams, 1992), one of a family of policy gradient methods from the
reinforcement learning literature, which approximates the gradient of Eq. 3 by drawing M trajectory
samples
∇J =
T∑
t=1
Eτ∼piθ(τ) [∇θ log piθ(lt|st)R] , (4)
≈ 1
M
M∑
i=1
T∑
t=1
∇ log piθ(lit|sit)Ri, (5)
with pi the agent’s policy mapping states to actions (in our case the location network), st the internal
representation of the recurrent network at time t, and i indexing sample number. Although seemingly
complex, Eq. 4 has a simple and pleasing interpretation: at each stage in the learning procedure
trajectories through a volumetric image are sampled from the current policy, with the parameters
adjusted such that actions (i.e location decisions) that led to a large reward are made more likely, and
those which didn’t are made less likely. In this way the agent learns to attend to the most informative
regions of the image, while avoiding those that provide little discriminative value.
5 Data and experimental details
To evaluate the effectiveness of our approach, we sought a disorder for which biomarkers have been
independently established and deep learning-based approaches for its diagnosis appear in the literature.
As such, we elected to evaluate NEURO-DRAM on the task of predicting Alzheimer’s disease from
structural magnetic resonance images, using data from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database. Although many publications have utilised this dataset for deep learning-
based classification, an objective comparison between these results and ours is challenging since
each of these separately employed i) different (and often unspecified) subsets of patients, ii) different
preprocessing pipelines, iii) different model inputs, and iv) different evaluation and cross-validation
procedures. We combat this issue of methodological heterogeneity, highlighted previously by Samper-
González et al. (2017), by instead fixing the architecture of our glimpse network to that of a
state-of-the-art convolutional model (Böhle et al, 2019), training and evaluating both models using
the same data and learning parameters (see Appendix 1 for a discussion about baseline selection).
This comparative approach, which is common in the machine learning literature, allows for a fair
comparison between the two models and avoids the well known phenomenon of over-fitting to
increasingly stale test sets through excessive hyper-parameter tuning (Recht et al. 2019). We
therefore restrict the scope of the present work to demonstrating the applicability of the approach for
an archetypical neuroimaging task, opening it up to other researchers to experiment with NEURO-
DRAM in other contexts, and to optimize hyper-parameter settings to maximise classification
performance. A NEURO-DRAM pytorch class is made available for this purpose at https://
github.com/neurodram/.
5.1 Data and preprocessing
The data used in this article was obtained from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI), which can be accessed at http://adni.loni.usc.edu. For our experiments we included
subjects from the ADNI-1 and ADNI-2 cohorts who were labelled as either ‘Alzheimer’s disease’
or ‘healthy control’. All scans were acquired using 1.5 Tesla scanners, and had undergone gradient
non-linearity, intensity homogeneity, and phantom-based distortion correction. For all patients we
downloaded the Magnetization Prepared Rapid Gradient-Echo (MPRAGE) T1-weighted images,
along with each patient’s demographic data (gender, age, ethnic and racial categories, and education),
cognitive performance measures (CDRSB, ADAS11, ADAS13, RAVLT), and APOe4 expression
indicator. In total, 322 patients were included (162 AD, 160 HC), for a total of 1012 images. These
were split into a training set (109 AD patients, 107 HCs; 797 images in total), a validation set (18
AD patients, 18 HCs; 100 images in total) and a test set (35 AD patients, 35 HCs; 70 images in
total). Following Böhle et al. (2019), we performed the data split at the level of participants to ensure
independence between training, validation, and test sets, with both models trained and evaluated using
6
these fixed data splits. Once downloaded, we perform brain extraction using DeepBrain, an open
source CNN-based skull stripping tool available at https://github.com/iitzco/deepbrain, as
well as non-linear registration to the reference Montreal Neurological Institute (MNI) 1 mm T1 brain
template using ANTsPy, an open-source python wrapper for Advanced Normalization Tools (Avants,
2009), available at https://github.com/ANTsX/ANTsPy.
5.2 Network architectures and training details
The baseline model is a convolutional neural network consisting of four convolutional blocks,
followed by two fully connected layers (Böhle et al. (2019)), taking as input the entire image volume.
Each block contains f filters (f = 8, 16, 32,64) of size 3 x 3 x 3, followed by batch normalization
(Ioffe and Szegedy, 2015) and max pooling (window size 4 x 4 x 4), while the fully connected layers
contain 128 and 2 units, respectively. A softmax activation function provides the probabilities for the
two classes, and the whole network is trained using the ADAM optimizer, with an initial learning
rate of 10−4 and exponential decay scheduling. Dropout is applied to the fully connected layers (p =
40%) during training, and L2 regularization is employed with a weight decay constant λ = 10−4.
The architecture of our glimpse network was fixed to that of the baseline described above. All hidden
layers in the location, recurrent, classification, and context networks had a dimensionality of 512,
with no experimentation of these settings performed. The number of glimpses the agent receives
was set to 6, with each glimpse of size 40 x 40 x 40 (∼ 1.6% of the entire image volume). No
regularization in the form of weight decay or drop-out was included. All other learning parameters
such as the optimization algorithm, learning rate, and scheduling were fixed to that of the baseline.
Both models were trained on the same training dataset using an NVIDIA RTX 2080Ti graphics
card, with no data augmentation performed. Early stopping was employed, with the best performing
checkpoint on the validation set for each model used to assess the final classification performance on
the same independent test set.
6 Results
NEURO-DRAM significantly outperforms the baseline model for Alzheimer’s disease prediction,
demonstrating a classification accuracy of 98.5% on the ADNI test set (Table 1). This is achieved
despite the fact that the agent sees less than 10% of each image, and without optimization of
architectural and learning hyper-parameters. By construction, the agent only uses the imaging
information to make its decision. We confirmed this behaviour by blanking the images and providing
only the clinical context information; in this case the algorithm performs no better than chance (54%),
as expected. Furthermore, we verified that backpropagated parameter gradients cannot flow from the
classification network to the non-imaging context network, confirming that classification optimization
on the basis of non-imaging information isn’t occurring.
Model NEURO-DRAM CNN baseline
Balanced accuracy 98.5% 87.5%
Specificity 100% 82%
Sensitivity 97.1% 86%
Maximum mini-batch size 60 6
Training time (per epoch) 45 seconds 241 seconds
Table 1: Classification performance of NEURO-DRAM and a fully convolutional baseline (Böhle
(2019)).
NEURO-DRAM also out-performs all previously reported deep-learning-based models, including
those incorporating both structural MRI and PET data (Jo et al. (2019) (Table 2).
To test the generalization performance of NEURO-DRAM on truly independent, out-of-sample
data, we applied it to subjects from the Open Access Series of Imaging Studies (OASIS) database
(all participants from the OASIS-1 cohort were included, consisting of 100 AD and 130 HC, one
image per participant, available at http://www.oasis-brains.org/). Because less additional
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Reference Modality Model AD vs. HC accuracy
Current study MRI NEURO-DRAM 98.5%
Cheng et al. (2018) MRI 3D CNN 87.15%
Wegmayr et al. (2017) MRI 3D CNN 86%
Korolev et al. (2017) MRI 3D CNN 80%
Suk et al. (2015) MRI, PET DBM 95.35%
Li et al (2014) MRI, PET SAE 92.8%
Liu et al (2015) MRI, PET SAE 91.4%
Vu et al. (2017) MRI, PET SAE + 3D CNN 91.14%
Cheng and Liu (2017) MRI, PET 3D CNN + 2D CNN 89.6%
Lu et al. (2018) MRI, PET DNN + NN 84.6%
Table 2: Comparison between NEURO-DRAM and previously reported models.
non-imaging data is available for images from this database (it is missing, for example, genetic and
ethnic information, as well as cognitive performance measures like ADAS and RAVLT scores), this
task also provides a test of our model’s ability to handle variable, missing or incomplete clinical and
demographic information. Instead of retraining the agent to incorporate only the non-imaging data
common to both databases, for each OASIS test set participant we set the missing data to be equal to
that of the most similar ADNI participant, as quantified by the cosine similarity across the remaining
fields in common (age, gender, cognitive score (CDR), education). This allows the agent to draw on
previous experience when conditioning it’s trajectory, but forbids it from using this imputed data
for the classification decision. It is plausible that this is similar to the manner in which a radiologist
might deal with missing or incomplete non-imaging information.
NEURO-DRAM generalizes well to the independent OASIS dataset, with no reduction in classifi-
cation accuracy when compared to the ADNI test set. This is in contrast to the fully convolutional
baseline, which performs considerably worse (Table 3). To the best of our knowledge, this is the
highest reported generalization accuracy using an external, out-of-sample test set.
Model NEURO-DRAM CNN baseline
Accuracy 99.8% 71.3%
Specificity 100% 85%
Sensitivity 99% 50%
Table 3: Generalization performance to OASIS test set
Unlike convolutional networks, NEURO-DRAM offers a clear insight into its classification decision.
By visualising the agent’s trajectory the most discriminative anatomical regions for Alzheimer’s
disease prediction can be obtained, providing a natural form of evidence for the algorithm’s decision.
Interestingly, the agent learns to first attend to the medial temporal lobe, before moving posteriorly
to the temporoparietal cortex (Fig. 2 and Fig. 3). By following this trajectory, the agent receives
glimpses of the hippocampus, parahippocampal gyrus, lateral ventricles and parietal cortex, volume
loss in which regions has been correlated with Alzheimer’s disease in many studies (Kesslak et al.,
1991, Smith and Jobust, 1996, Jack et al., 1997, Nagy et al., 1999, Apostolova et al., 2012, Van
Hoesen et al., 2000, Jacobs et al., 2012).
As a final test of our agent’s policy we apply it, without additional training, to the task of predicting
which patients with mild cognitive impairment (MCI) will progress to Alzheimer’s disease within
two years of clinical assessment. Because some forms of MCI are clinical precursors of Alzheimer’s
disease, it is plausible that the search policy followed by our agent could also help identify those
patients at risk of progression. To this end, we freeze the weights of both NEURO-DRAM and the
fully convolutional baseline following AD vs. HC training, and apply these models to an independent
test set comprising 36 previously unseen patients from the ADNI database, 18 of which had MCI at
the time of their baseline scan and went on to develop Alzheimer’s disease within two years, and
18 of which had MCI but did not progress. Again, NEURO-DRAM significantly outperforms the
baseline architecture, demonstrating a classification accuracy of 77.8%, versus only 63% for the fully
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Figure 2: Trajectory taken by the agent for three representative participants from the ADNI test
set (one per row). A bounding box around the first location attended to is included to indicate the
approximate size of the glimpse that the agent receives; this is the same for all subsequent locations
By taking this path, the agent receives glimpses of the hippocampus, parahippocampal gyrus, lateral
ventricles and parietal cortex, regions known to be affected by Alzheimer’s disease.
Figure 3: Coronal slice through the first glimpse taken by the agent for two Alzheimer’s disease
subjects, i), ii), and one healthy control, iii), from the ADNI test set. By attending to this region, the
agent observes the hippocampus and parahippocampal gyrus. Atrophy in this region is a radiological
biomarker of Alzheimer’s disease, as can be seen in i) and ii).
convolutional model, suggesting that the locations attended to by the agent are informative for both
early and advanced stages of the disease. To our knowledge, this is the highest classification accuracy
for predicting progression of MCI from structural MRI scans only (Jo et al., (2019)), despite the fact
that the agent was not explicitly trained using any MCI data.
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Reference Modality Model AD vs. HC accuracy
Current study MRI NEURO-DRAM 77.8%
Liu et al. (2018b) MRI Landmark detection & 3D CNN 76.9%
Basaia et al. (2019) MRI 3D CNN 75%
Spasov et al. (2010) MRI 3D CNN 72%
Table 4: Comparison between NEURO-DRAM and previously reported models for MCI conversion
prediction.
7 Discussion
Our novel model introduced in this paper addresses a number of issues associated with using fully
convolutional architectures for three-dimensional neuroimaging data. As a result, it outperforms a
state-of-the-art baseline architecture at the task of Alzheimer’s disease classification, despite very
limited hyper-parameter tuning. NEURO-DRAM also generalizes well to an independent dataset; an
essential goal if machine-learning analysis of neuroimaging data is ever to be deployed in a clinical
setting. This improved performance can be traced to the agent learning to attend to highly informative
volumes within an image while avoiding those providing little discriminative value, thereby reducing
the effects of overfitting. The increased usable batch sizes and faster training of our model also
affords much greater scalability to large neuroimaging datasets, with training times less than ten
minutes for the dataset presented in this paper, compared with over 45 minutes for the baseline model.
This is due to the smaller number of computations and more stable gradient updates performed by
NEURO-DRAM. The model’s state-of-the-art performance is also achieved without any form of data
augmentation or model regularization. This is important because it requires less hyper-parameter
tuning (L2 penalty coefficient, drop-out probability, etc.) to optimize model performance, and avoids
the introduction of unnatural and task-dependent data transformations such as deformations and
cropping.
Perhaps most importantly, NEURO-DRAM offers a clear insight into its classification decision. While
the validity of these model decisions will require further investigation, we believe NEURO-DRAM has
great promise to provide sufficient interpretability to reach a level of acceptance in clinical settings. As
shown in Fig. 2, the agent primarily visits the medial temporal cortex and the temporoparietal region,
and by doing so receives views of the hippocampus, parahippocampal gyrus, lateral ventricles and
parietal cortex, regions known to be affected by Alzheimer’s disease-related neuronal atrophy. In fact,
clinical hallmarks for diagnosing Alzheimer’s disease are based on standardized assessments of these
very regions, with the Koedam score for parietal atrophy (Koedman et al., 2011) and the MTA scale for
medial temporal atrophy widely used by clinical radiologists (Scheltens et al. (1995)). That the agent
learns to attend to these known biomarkers for Alzheimer’s disease suggests that it is functioning
in way that is analogous to how a radiologist may view images when considering a diagnosis of
Alzheimer’s disease. Furthermore, because the neuroanatomical regions utilised by the model can be
readily visualised, when applied to less well-characterised psychiatric and neurological disorders the
trajectory taken by the agent can be considered as representing feature/location importance, offering
a novel route to automated biomarker discovery.
Several straight-forward extensions to the existing model are also possible. A key feature of NEURO-
DRAM is the ability to include non-imaging meta-data. While here we included only numerical
and categorical clinical and demographic information, clinical history in the form of structured
radiological reports, or even free text, could be incorporated by replacing the fully-connected context
network with, for instance, a language embedding module such as word2vec (Mikolov et al 2013) or
doc2vec (Le and Mikolov, 2014). NEURO-DRAM could also be employed recursively for multi-
modal analysis. In this case, instead of providing a classification decision at the final step, the hidden
state of the upper LSTM unit would become the initial context vector for the next modality (e.g.,
a PET scan, a different MRI sequence, or even a lumbar puncture for CSF biomarker analysis),
guiding the search by keeping in mind what it has seen in the structural MR image. Finally, the
classification network can also be modified to output a decision as soon as it is sufficiently confident
of its prediction by incorporating a negative reward at each time step. In this way, the agent would
attend to additional regions (or other imaging modalities) only if this will considerably improve the
certainty of it’s decision. This feature has potentially important implications for clinical practice,
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as the cost and invasiveness of each modality can be considered. This way, unnecessary clinical
investigations can be reduced and only as much data as is required for a given clinical decision is
acquired, reducing costs and patient discomfort.
8 Conclusion
Here we present NEURO-DRAM, a 3D recurrent visual attention model tailored for neuroimaging
data. The results in the analysis of Alzheimer’s disease and MCI suggest that this reinforcement
learning approach has considerable promise for improving model performance, for combining
neuroimaging and meta-data and for providing intuitive interpretability of how the model reaches
decisions.
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9 Appendix
Selection of Baseline model
This model was selected on the basis of classification accuracy, taking into account methodological transparency.
Although several papers have reported classification accuracies above 90% using multiple scans per participant
(Gupta et al. (2013), Payen et al. (2015), Hosseini et al. (2016), and Basaia et al. (2019)), in all cases the
authors failed to explicitly state how the split into training, validation, and test sets was performed. As shown
by Wagmayr et al. (2018), if the data is shuffled at the level of images rather than participants, classification
accuracy dramatically increases - in their case from 86% to over 98%. This occurs because the model is
seeing participants in the test set that it saw during training, resulting in an overly optimistic estimate of its
generalization performance. Interestingly, all publications which explicitly state that the correct data split was
performed achieved significantly lower classification accuracies, calling into question the performance of those
that failed to do so. For this reason, the models of Gupta et al. (2013), Payen et al. (2015), Hosseini et al. (2016),
and Basaia et al. (2019) was deemed ineligible for consideration as a state-of-the-art baseline.
Of the remaining publications that are methodologically transparent, Böhle et al. (2019) reported the highest
classification accuracy. As such, we selected their model as a state-of-the-art baseline for comparison with
NEURO-DRAM.
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